G1 Therapeutics Inc to Discuss PRESERVE 1 and the Company's Ongoing Commercial and Clinical Programs Call Transcript
Good morning, ladies and gentlemen, and welcome to the G1 Therapeutics conference call. (Operator Instructions) I would now like to turn the conference over to your host today, Will Roberts, Head of Corporate Communications. Sir, please go ahead.
Thank you, Michelle, and thank you all for joining us this morning on our conference call to discuss the top line results of PRESERVE 1 in colorectal cancer. The press release on these results was issued this morning and can be found in the News section of our corporate website, g1therapeutics.com. A Q&A session will follow the prepared remarks.
Before we begin, I want to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment, expectations and assumptions as of today and may involve risks and uncertainties that could cause actual results to differ materially from those expressed in or
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |